Skip to main content
Erschienen in: Endocrine 3/2017

03.06.2016 | Endocrine Trials

Rationale and design of the Early Sleeve gastrectomy In New Onset Diabetic Obese Patients (ESINODOP) trial

verfasst von: Stefano Trastulli, Jacopo Desiderio, Ilenia Grandone, Lucia Fontana, Luisa Paolini, Maria Altomare, Paola D’Angelo, Mariangela Palazzi, Roberto Cirocchi, Sergio Leotta, Giuseppe Fatati, Amilcare Parisi, on behalf of the ESINODOP trial Investigators

Erschienen in: Endocrine | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

No randomized clinical trials (RCTs) have yet evaluated the bariatric surgery’s efficacy and safety in patients newly diagnosed with type 2 diabetes mellitus (T2DM). The aim of this multicenter RCT is to compare bariatric surgery, particularly laparoscopic sleeve gastrectomy (LSG), with conventional medical therapy (CMT) in obese patients (body mass index between 30 and 42 kg/m2) newly diagnosed with T2DM and without any diabetes-related complications at any stage. A total of 100 eligible patients will be randomized at a 1:1 ratio to undergo one of the two planned treatments and will be followed for at least 6 years after randomization. The main objective of the ESINODOP trial is to investigate the efficacy of LSG compared with CMT alone in inducing and maintaining a remission of T2DM (defined as HbA1c levels ≤6.0 %, without active pharmacologic therapy after 1 year). The remission of T2DM will also be evaluated with the criteria provided by the American Diabetes Association (ADA), and the additional parameters such as adverse event rates, micro- and macrovascular complications, weight loss, gastrointestinal hormones, and quality of life will be compared. The study started on September 2015 and the planned recruitment period is 3 years. Patient recruitment and follow-up take place in the two diabetology and nutrition centers participating in the study, which are performed on a national basis. The ESINODOP trial is designed with the intent of comparing the efficacy of CMT alone to that of CMT in conjunction with LSG performed at the time of diabetes diagnosis in mildly obese diabetic patients. Currently, patients with these characteristics are not eligible for bariatric/metabolic surgery.
Literatur
4.
Zurück zum Zitat R.C. Turner, C.A. Cull, V. Frighi, R.R. Holman, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21), 2005–2012 (1999)CrossRefPubMed R.C. Turner, C.A. Cull, V. Frighi, R.R. Holman, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21), 2005–2012 (1999)CrossRefPubMed
5.
Zurück zum Zitat S.S. Casagrande, J.E. Fradkin, S.H. Saydah, K.F. Rust, C.C. Cowie, The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes care 36(8), 2271–2279 (2013). doi:10.2337/dc12-2258 CrossRef S.S. Casagrande, J.E. Fradkin, S.H. Saydah, K.F. Rust, C.C. Cowie, The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes care 36(8), 2271–2279 (2013). doi:10.​2337/​dc12-2258 CrossRef
6.
Zurück zum Zitat P.R. Schauer, S.R. Kashyap, K. Wolski, S.A. Brethauer, J.P. Kirwan, C.E. Pothier, S. Thomas, B. Abood, S.E. Nissen, D.L. Bhatt, Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366(17), 1567–1576 (2012). doi:10.1056/NEJMoa1200225 CrossRefPubMedPubMedCentral P.R. Schauer, S.R. Kashyap, K. Wolski, S.A. Brethauer, J.P. Kirwan, C.E. Pothier, S. Thomas, B. Abood, S.E. Nissen, D.L. Bhatt, Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366(17), 1567–1576 (2012). doi:10.​1056/​NEJMoa1200225 CrossRefPubMedPubMedCentral
8.
9.
Zurück zum Zitat J.B. Buse, S. Caprio, W.T. Cefalu, A. Ceriello, S. Del Prato, S.E. Inzucchi, S. McLaughlin, G.L. Phillips 2nd, R.P. Robertson, F. Rubino, R. Kahn, M.S. Kirkman, How do we define cure of diabetes? Diabetes Care 32(11), 2133–2135 (2009). doi:10.2337/dc09-9036 CrossRefPubMedPubMedCentral J.B. Buse, S. Caprio, W.T. Cefalu, A. Ceriello, S. Del Prato, S.E. Inzucchi, S. McLaughlin, G.L. Phillips 2nd, R.P. Robertson, F. Rubino, R. Kahn, M.S. Kirkman, How do we define cure of diabetes? Diabetes Care 32(11), 2133–2135 (2009). doi:10.​2337/​dc09-9036 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat A.D. Miras, H. Risstad, N. Baqai, S. Law, T.T. Sovik, T. Mala, T. Olbers, J.A. Kristinsson, C.W. le Roux, Application of the International Diabetes Federation and American Diabetes Association criteria in the assessment of metabolic control after bariatric surgery. Diabetes Obes. Metab. 16(1), 86–89 (2014). doi:10.1111/dom.12177 CrossRefPubMed A.D. Miras, H. Risstad, N. Baqai, S. Law, T.T. Sovik, T. Mala, T. Olbers, J.A. Kristinsson, C.W. le Roux, Application of the International Diabetes Federation and American Diabetes Association criteria in the assessment of metabolic control after bariatric surgery. Diabetes Obes. Metab. 16(1), 86–89 (2014). doi:10.​1111/​dom.​12177 CrossRefPubMed
13.
Zurück zum Zitat D.E. Arterburn, A. Bogart, N.E. Sherwood, S. Sidney, K.J. Coleman, S. Haneuse, P.J. O’Connor, M.K. Theis, G.M. Campos, D. McCulloch, J. Selby, A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes. Surg. 23(1), 93–102 (2013). doi:10.1007/s11695-012-0802-1 CrossRefPubMedPubMedCentral D.E. Arterburn, A. Bogart, N.E. Sherwood, S. Sidney, K.J. Coleman, S. Haneuse, P.J. O’Connor, M.K. Theis, G.M. Campos, D. McCulloch, J. Selby, A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes. Surg. 23(1), 93–102 (2013). doi:10.​1007/​s11695-012-0802-1 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat L. Sjostrom, M. Peltonen, P. Jacobson, S. Ahlin, J. Andersson-Assarsson, A. Anveden, C. Bouchard, B. Carlsson, K. Karason, H. Lonroth, I. Naslund, E. Sjostrom, M. Taube, H. Wedel, P.A. Svensson, K. Sjoholm, L.M. Carlsson, Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311(22), 2297–2304 (2014). doi:10.1001/jama.2014.5988 CrossRefPubMed L. Sjostrom, M. Peltonen, P. Jacobson, S. Ahlin, J. Andersson-Assarsson, A. Anveden, C. Bouchard, B. Carlsson, K. Karason, H. Lonroth, I. Naslund, E. Sjostrom, M. Taube, H. Wedel, P.A. Svensson, K. Sjoholm, L.M. Carlsson, Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311(22), 2297–2304 (2014). doi:10.​1001/​jama.​2014.​5988 CrossRefPubMed
15.
Zurück zum Zitat S. Panunzi, L. Carlsson, A. De Gaetano, M. Peltonen, T. Rice, L. Sjostrom, G. Mingrone, J.B. Dixon, Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 39(1), 166–174 (2016). doi:10.2337/dc15-0575 CrossRefPubMed S. Panunzi, L. Carlsson, A. De Gaetano, M. Peltonen, T. Rice, L. Sjostrom, G. Mingrone, J.B. Dixon, Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 39(1), 166–174 (2016). doi:10.​2337/​dc15-0575 CrossRefPubMed
16.
Zurück zum Zitat M.T. Lund, M. Hansen, S. Skaaby, S. Dalby, M. Stockel, A.K. Floyd, K. Bech, J.W. Helge, J.J. Holst, F. Dela, Preoperative beta-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery. J. Physiol. 593(14), 3123–3133 (2015). doi:10.1113/JP270264 CrossRefPubMedPubMedCentral M.T. Lund, M. Hansen, S. Skaaby, S. Dalby, M. Stockel, A.K. Floyd, K. Bech, J.W. Helge, J.J. Holst, F. Dela, Preoperative beta-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery. J. Physiol. 593(14), 3123–3133 (2015). doi:10.​1113/​JP270264 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat M. Nannipieri, S. Baldi, A. Mari, D. Colligiani, D. Guarino, S. Camastra, E. Barsotti, R. Berta, D. Moriconi, R. Bellini, M. Anselmino, E. Ferrannini, Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98(11), 4391–4399 (2013). doi:10.1210/jc.2013-2538 CrossRefPubMed M. Nannipieri, S. Baldi, A. Mari, D. Colligiani, D. Guarino, S. Camastra, E. Barsotti, R. Berta, D. Moriconi, R. Bellini, M. Anselmino, E. Ferrannini, Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98(11), 4391–4399 (2013). doi:10.​1210/​jc.​2013-2538 CrossRefPubMed
19.
Zurück zum Zitat S. Trastulli, J. Desiderio, S. Guarino, R. Cirocchi, V. Scalercio, G. Noya, A. Parisi, Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg. Obes. Relat. Dis. 9(5), 816–829 (2013). doi:10.1016/j.soard.2013.05.007 CrossRefPubMed S. Trastulli, J. Desiderio, S. Guarino, R. Cirocchi, V. Scalercio, G. Noya, A. Parisi, Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg. Obes. Relat. Dis. 9(5), 816–829 (2013). doi:10.​1016/​j.​soard.​2013.​05.​007 CrossRefPubMed
21.
Zurück zum Zitat J.I. Mechanick, A. Youdim, D.B. Jones, W.T. Garvey, D.L. Hurley, M.M. McMahon, L.J. Heinberg, R. Kushner, T.D. Adams, S. Shikora, J.B. Dixon, S. Brethauer, American Association of Clinical E, Obesity S, Bariatric S, Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity 21(Suppl 1), S1–S27 (2013). doi:10.1002/oby.20461 CrossRefPubMedPubMedCentral J.I. Mechanick, A. Youdim, D.B. Jones, W.T. Garvey, D.L. Hurley, M.M. McMahon, L.J. Heinberg, R. Kushner, T.D. Adams, S. Shikora, J.B. Dixon, S. Brethauer, American Association of Clinical E, Obesity S, Bariatric S, Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity 21(Suppl 1), S1–S27 (2013). doi:10.​1002/​oby.​20461 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat J.B. Dixon, P.E. O’Brien, J. Playfair, L. Chapman, L.M. Schachter, S. Skinner, J. Proietto, M. Bailey, M. Anderson, Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299(3), 316–323 (2008). doi:10.1001/jama.299.3.316 CrossRefPubMed J.B. Dixon, P.E. O’Brien, J. Playfair, L. Chapman, L.M. Schachter, S. Skinner, J. Proietto, M. Bailey, M. Anderson, Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299(3), 316–323 (2008). doi:10.​1001/​jama.​299.​3.​316 CrossRefPubMed
Metadaten
Titel
Rationale and design of the Early Sleeve gastrectomy In New Onset Diabetic Obese Patients (ESINODOP) trial
verfasst von
Stefano Trastulli
Jacopo Desiderio
Ilenia Grandone
Lucia Fontana
Luisa Paolini
Maria Altomare
Paola D’Angelo
Mariangela Palazzi
Roberto Cirocchi
Sergio Leotta
Giuseppe Fatati
Amilcare Parisi
on behalf of the ESINODOP trial Investigators
Publikationsdatum
03.06.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0996-4

Weitere Artikel der Ausgabe 3/2017

Endocrine 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.